CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands - PubMed (original) (raw)
CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands
C Castaldo et al. J Biomol Screen. 2014 Jul.
Abstract
The CXC chemokine receptor 4 (CXCR4) is a widely expressed G protein-coupled receptor implicated in several diseases. In cancer, an increased number of surface CXCR4 receptors, in parallel with aberrant signaling, have been reported to influence several aspects of malignancy progression. CXCR4 activation by the specific ligand C-X-C motif chemokine 12 (CXCL12) induces several intracellular signaling pathways that have been selectively related to malignancy depending on the tissue or cell type. We developed a panel of CXCR4 screening assays investigating Gα(i)-mediated cyclic adenosine monophosphate modulation, β-arrestin recruitment, and receptor internalization. All of the assays were set up in recombinant cells and were used to test four reported CXCR4 antagonists. Consequently, a set of hit compounds, deriving from a screening campaign of a 30,000-small-molecule internal library, was profiled with the different assays. We identified several compounds showing a pathway-selective activity: antagonists on a Gα(i)-dependent pathway; antagonists on both the β-arrestin and Gα(i)-dependent pathways, some of which induce receptor internalization; and compounds with an antagonist behavior in all of the readouts. The identified biased antagonists induce different functional states on CXCR4 and preferentially affect specific downstream responses from the activated receptor, thus providing an improved therapeutic profile for correction of CXCR4 abnormal signaling.
Keywords: AMD3100; CXC chemokine receptor 4 (CXCR4); G protein–coupled receptor (GPCR); biased antagonism; cyclic adenosine monophosphate (cAMP); glioblastoma multiforme (GBM); high-content screening (HCS); homogeneous time-resolved fluorescence (HTRF); receptor internalization; β-arrestin.
© 2014 Society for Laboratory Automation and Screening.
Similar articles
- Biased antagonism of CXCR4 avoids antagonist tolerance.
Hitchinson B, Eby JM, Gao X, Guite-Vinet F, Ziarek JJ, Abdelkarim H, Lee Y, Okamoto Y, Shikano S, Majetschak M, Heveker N, Volkman BF, Tarasova NI, Gaponenko V. Hitchinson B, et al. Sci Signal. 2018 Oct 16;11(552):eaat2214. doi: 10.1126/scisignal.aat2214. Sci Signal. 2018. PMID: 30327409 Free PMC article. - beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1.
van Der Lee MM, Bras M, van Koppen CJ, Zaman GJ. van Der Lee MM, et al. J Biomol Screen. 2008 Dec;13(10):986-98. doi: 10.1177/1087057108326144. Epub 2008 Nov 25. J Biomol Screen. 2008. PMID: 19036707 - Atypical Chemokine Receptor 3 "Senses" CXC Chemokine Receptor 4 Activation Through GPCR Kinase Phosphorylation.
Schafer CT, Chen Q, Tesmer JJG, Handel TM. Schafer CT, et al. Mol Pharmacol. 2023 Oct;104(4):174-186. doi: 10.1124/molpharm.123.000710. Epub 2023 Jul 20. Mol Pharmacol. 2023. PMID: 37474305 Free PMC article. - Inhibitors of CXC chemokine receptor type 4: putative therapeutic approaches in inflammatory diseases.
Hummel S, Van Aken H, Zarbock A. Hummel S, et al. Curr Opin Hematol. 2014 Jan;21(1):29-36. doi: 10.1097/MOH.0000000000000002. Curr Opin Hematol. 2014. PMID: 24275689 Review. - Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
Oishi S, Fujii N. Oishi S, et al. Org Biomol Chem. 2012 Aug 14;10(30):5720-31. doi: 10.1039/c2ob25107h. Epub 2012 Apr 19. Org Biomol Chem. 2012. PMID: 22517031 Review.
Cited by
- The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?
Abbasifard M, Bagherzadeh K, Khorramdelazad H. Abbasifard M, et al. Front Pharmacol. 2024 Jul 12;15:1410104. doi: 10.3389/fphar.2024.1410104. eCollection 2024. Front Pharmacol. 2024. PMID: 39070795 Free PMC article. Review. - Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands.
Shpakov AO. Shpakov AO. Int J Mol Sci. 2023 Mar 24;24(7):6187. doi: 10.3390/ijms24076187. Int J Mol Sci. 2023. PMID: 37047169 Free PMC article. Review. - Modified chitosan for effective renal delivery of siRNA to treat acute kidney injury.
Tang W, Panja S, Jogdeo CM, Tang S, Ding L, Yu A, Foster KW, Dsouza DL, Chhonker YS, Jensen-Smith H, Jang HS, Boesen EI, Murry DJ, Padanilam B, Oupický D. Tang W, et al. Biomaterials. 2022 Jun;285:121562. doi: 10.1016/j.biomaterials.2022.121562. Epub 2022 May 2. Biomaterials. 2022. PMID: 35552115 Free PMC article. - Targeting CXCR4 in AML and ALL.
Cancilla D, Rettig MP, DiPersio JF. Cancilla D, et al. Front Oncol. 2020 Sep 4;10:1672. doi: 10.3389/fonc.2020.01672. eCollection 2020. Front Oncol. 2020. PMID: 33014834 Free PMC article. Review. - Biased antagonism of CXCR4 avoids antagonist tolerance.
Hitchinson B, Eby JM, Gao X, Guite-Vinet F, Ziarek JJ, Abdelkarim H, Lee Y, Okamoto Y, Shikano S, Majetschak M, Heveker N, Volkman BF, Tarasova NI, Gaponenko V. Hitchinson B, et al. Sci Signal. 2018 Oct 16;11(552):eaat2214. doi: 10.1126/scisignal.aat2214. Sci Signal. 2018. PMID: 30327409 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources